Macrogenics Inc (NASDAQ: MGNX) on Tuesday, soared 3.05% from the previous trading day, before settling in for the closing price of $1.64. Within the past 52 weeks, MGNX’s price has moved between $0.99 and $5.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 19.47% over the last five years. The company achieved an average annual earnings per share of -55.61%. With a float of $57.94 million, this company’s outstanding shares have now reached $63.09 million.
The firm has a total of 341 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.78%, operating margin of -65.25%, and the pretax margin is -36.0%.
Macrogenics Inc (MGNX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Macrogenics Inc is 8.16%, while institutional ownership is 78.96%. The most recent insider transaction that took place on Feb 15 ’25, was worth 1,083. In this transaction VP, Controller & Treasurer of this company sold 423 shares at a rate of $2.56, taking the stock ownership to the 9,532 shares.
Macrogenics Inc (MGNX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -55.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -25.45% during the next five years compared to 19.47% growth over the previous five years of trading.
Macrogenics Inc (NASDAQ: MGNX) Trading Performance Indicators
Macrogenics Inc (MGNX) is currently performing well based on its current performance indicators. A quick ratio of 3.11 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.73 in one year’s time.
Technical Analysis of Macrogenics Inc (MGNX)
Analysing the last 5-days average volume posted by the [Macrogenics Inc, MGNX], we can find that recorded value of 0.81 million was lower than the volume posted last year of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 40.65%.
During the past 100 days, Macrogenics Inc’s (MGNX) raw stochastic average was set at 49.12%, which indicates a significant decrease from 53.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1273 in the past 14 days, which was lower than the 0.1391 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5011, while its 200-day Moving Average is $2.3748.
